CLAIM AMENDMENTS

1. (currently amended): A compound of formula I



I

or a pharmaceutically acceptable ~~salts or diastereomers~~ salt or diastereomer thereof, wherein:

A is NR^1, where R^1 is H, or C_{1-4} alkyl;

B is phenyl optionally substituted with 0-4 substituents independently selected from halogen, C_{1-4} alkyl, CF_3, CN, aryl, OH, OCF_3, OC_{1-4} alkyl, OC_{2-5} alkylNR^2R^3, Oaryl, CO_2R^2, $CONR^2R^3$, NR^2R^3, NR^4C_{1-4} alkylNR^2R^3, NR^2COR^3, $OC(O)NR^2R^3$, $NR^4CONR^2R^3$, and $NR^2SO_2R^3$;

wherein R^2, R^3 are each independently H, C_{1-4} alkyl, aryl, C_{1-4} alkyl aryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing one of O, S, or NR^5;

wherein R^4 is H or C_{1-4} alkyl; and

wherein R^5 is H or C_{1-4} alkyl;

Q is a bond when W is absent, and is C_{1-4} alkyl when W is present;

W is selected from H, C_{1-4} alkyl, C_{2-6} alkenyl; where C_{1-4} alkyl or C_{2-6} alkenyl may be optionally substituted with C_{1-4} alkyl, OH, OC_{1-4} alkyl, $NR^6C(O)R^7$, $CONR^6R^7$, OR^6, or NR^6R^7;

wherein R^6, and R^7 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, aryl, or may be joined to form an optionally substituted 3-8 membered ring, and

Y is [[H or]] phenyl, optionally substituted with 0-3 substituents independently selected from halogen, C_{1-4} alkyl, CF_3, aryl, OH, OCF_3, CN, C_{2-4} alkynyl, OC_{1-4} alkyl, OC_{2-5} alkylNR^9R^{10}, Oaryl, [[CO_2R^9,]] $CONR^9R^{10}$, NR^9R^{10}, C_{1-4} alkylNR^9R^{10}, $NR^{11}C_{1-4}$ alkylNR^9R^{10}, NR^9COR^{10}, $NR^{11}CONR^9R^{10}$, and $NR^9SO_2R^{10}$;

wherein R^9 and R^{10} is each independently H, C_{1-4} alkyl, aryl, C_{1-4} alkyl aryl, or may be joined to form an optionally substituted 3-8 membered ring;

wherein R^{11} is H or C_{1-4} alkyl[[;]]

~~with the proviso that when Y is phenyl substituted at the ortho position with CO_2R^9, CN or NH_2, W is absent and Q is a bond, and B has one or zero substituents, then R^1 is C_{1-4} alkyl~~.

2. (currently amended): A compound according to claim 1 or a pharmaceutically acceptable ~~salts or diastereomers~~ salt or diastereomer thereof, wherein:

W is selected from H, C_{1-4} alkyl, and C_{2-6} alkenyl; wherein C_{1-4} alkyl or C_{2-6} alkenyl may be optionally substituted with C_{1-4} alkyl, OH, OC_{1-4} alkyl, or NR^6R^7;

wherein R^6, and R^7 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, aryl, or may be joined to form an optionally substituted 3-8 membered ring;

Y is [[H or]] phenyl optionally substituted with 0-3 substituents independently selected from halogen, C_{1-4} alkyl, CF_3, aryl, OH, OCF_3, OC_{1-4} alkyl, OC_{2-5} alkylNR^9R^{10}, Oaryl, [[CO_2R^9,]] $CONR^9R^{10}$, NR^9R^{10}, C_{1-4} alkylNR^9R^{10}, $NR^{11}C_{1-4}$ alkylNR^9R^{10}, NR^9COR^{10}, $NR^{11}CONR^9R^{10}$, and $NR^9SO_2R^{10}$;

wherein R^9, and R^{10} are each independently H, C_{1-4} alkyl, aryl, C_{1-4} alkyl aryl, or may be joined to form an optionally substituted 3-8 membered ring; and

wherein R^{11} is H or C_{1-4} alkyl.

3. (currently amended): A compound ~~according to claim 1 wherein the compound is~~ selected from the group consisting of:



C22H22N2O4



C23H23ClN2O4



C20H18N2O2



C22H20ClFN2O4



C19H15FN2O2



C22H20ClFN2O4



C19H16N2O2



C22H21ClN2O4



C20H19N3O2



C23H24N2O4



C21H19FN2O2



C19H18N2O3



C22H22N2O2



C21H19FN2O2



C21H20N2O2



C21H20N2O2



C21H20N2O2



C22H22N2O3



C21H20N2O2



C20H17FN2O2



C20H17FN2O2



C20H18N2O2



C19H16N2O2



C21H20N2O3



C22H22N2O4



C20H17FN2O3



C20H17FN2O3



C21H20N2O3



C20H18N2O3

[[or]] and a pharmaceutically acceptable ~~salts or diastereomers~~ salt or diastereomer thereof.

4. (previously presented): A pharmaceutical composition comprising a carrier and at least one compound of claim 1.

5-6. (canceled)

7. (previously presented): A pharmaceutical composition comprising a carrier and at least one compound of claim 2.

8. (previously presented): A pharmaceutical composition comprising a carrier and at least one compound of claim 3.